Evaluation of candidate molecular alterations underlying tumor inhibition revealed significantly lower HRH1 levels in the loratadine‐treated tumors, and higher levels of the mitochondrial fission marker phospho‐Ser616 DRP1 in the rasagiline‐treated tumors, with a similar trend in the two other monotherapy settings (Fig 7A). Here, HRH1 is linked to neoplasm.